Abstract
Summary
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The global Follicular Lymphoma Therapeutic market size is projected to grow from US$ 1673.9 million in 2023 to US$ 2163.7 million in 2030; it is expected to grow at a CAGR of 3.7% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Follicular Lymphoma Therapeutic Industry Forecast” looks at past sales and reviews total world Follicular Lymphoma Therapeutic sales in 2023, providing a comprehensive analysis by region and market sector of projected Follicular Lymphoma Therapeutic sales for 2024 through 2030. With Follicular Lymphoma Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Follicular Lymphoma Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Follicular Lymphoma Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Follicular Lymphoma Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Follicular Lymphoma Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Follicular Lymphoma Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Follicular Lymphoma Therapeutic.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Follicular Lymphoma Therapeutic market by product type, application, key players and key regions and countries.
Segmentation by type
ChemOthersapy
RadiOthersapy
Monoclonal Antibodies
Stem Cell Transplantation
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Biogen
F. Hoffmann-La Roche
Gilead
Merck
Celldex
Boehringer Ingelheim
Bristol-Myers Squibb
The global Follicular Lymphoma Therapeutic market size is projected to grow from US$ 1673.9 million in 2023 to US$ 2163.7 million in 2030; it is expected to grow at a CAGR of 3.7% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Follicular Lymphoma Therapeutic Industry Forecast” looks at past sales and reviews total world Follicular Lymphoma Therapeutic sales in 2023, providing a comprehensive analysis by region and market sector of projected Follicular Lymphoma Therapeutic sales for 2024 through 2030. With Follicular Lymphoma Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Follicular Lymphoma Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Follicular Lymphoma Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Follicular Lymphoma Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Follicular Lymphoma Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Follicular Lymphoma Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Follicular Lymphoma Therapeutic.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Follicular Lymphoma Therapeutic market by product type, application, key players and key regions and countries.
Segmentation by type
ChemOthersapy
RadiOthersapy
Monoclonal Antibodies
Stem Cell Transplantation
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Biogen
F. Hoffmann-La Roche
Gilead
Merck
Celldex
Boehringer Ingelheim
Bristol-Myers Squibb
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Follicular Lymphoma Therapeutic Market Size 2019-2030
2.1.2 Follicular Lymphoma Therapeutic Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Follicular Lymphoma Therapeutic Segment by Type
2.2.1 ChemOthersapy
2.2.2 RadiOthersapy
2.2.3 Monoclonal Antibodies
2.2.4 Stem Cell Transplantation
2.3 Follicular Lymphoma Therapeutic Market Size by Type
2.3.1 Follicular Lymphoma Therapeutic Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Follicular Lymphoma Therapeutic Market Size Market Share by Type (2019-2024)
2.4 Follicular Lymphoma Therapeutic Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Follicular Lymphoma Therapeutic Market Size by Application
2.5.1 Follicular Lymphoma Therapeutic Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Follicular Lymphoma Therapeutic Market Size Market Share by Application (2019-2024)
3 Follicular Lymphoma Therapeutic Market Size by Player
3.1 Follicular Lymphoma Therapeutic Market Size Market Share by Players
3.1.1 Global Follicular Lymphoma Therapeutic Revenue by Players (2019-2024)
3.1.2 Global Follicular Lymphoma Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Follicular Lymphoma Therapeutic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Follicular Lymphoma Therapeutic by Regions
4.1 Follicular Lymphoma Therapeutic Market Size by Regions (2019-2024)
4.2 Americas Follicular Lymphoma Therapeutic Market Size Growth (2019-2024)
4.3 APAC Follicular Lymphoma Therapeutic Market Size Growth (2019-2024)
4.4 Europe Follicular Lymphoma Therapeutic Market Size Growth (2019-2024)
4.5 Middle East & Africa Follicular Lymphoma Therapeutic Market Size Growth (2019-2024)
5 Americas
5.1 Americas Follicular Lymphoma Therapeutic Market Size by Country (2019-2024)
5.2 Americas Follicular Lymphoma Therapeutic Market Size by Type (2019-2024)
5.3 Americas Follicular Lymphoma Therapeutic Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Follicular Lymphoma Therapeutic Market Size by Region (2019-2024)
6.2 APAC Follicular Lymphoma Therapeutic Market Size by Type (2019-2024)
6.3 APAC Follicular Lymphoma Therapeutic Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Follicular Lymphoma Therapeutic by Country (2019-2024)
7.2 Europe Follicular Lymphoma Therapeutic Market Size by Type (2019-2024)
7.3 Europe Follicular Lymphoma Therapeutic Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Follicular Lymphoma Therapeutic by Region (2019-2024)
8.2 Middle East & Africa Follicular Lymphoma Therapeutic Market Size by Type (2019-2024)
8.3 Middle East & Africa Follicular Lymphoma Therapeutic Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Follicular Lymphoma Therapeutic Market Forecast
10.1 Global Follicular Lymphoma Therapeutic Forecast by Regions (2025-2030)
10.1.1 Global Follicular Lymphoma Therapeutic Forecast by Regions (2025-2030)
10.1.2 Americas Follicular Lymphoma Therapeutic Forecast
10.1.3 APAC Follicular Lymphoma Therapeutic Forecast
10.1.4 Europe Follicular Lymphoma Therapeutic Forecast
10.1.5 Middle East & Africa Follicular Lymphoma Therapeutic Forecast
10.2 Americas Follicular Lymphoma Therapeutic Forecast by Country (2025-2030)
10.2.1 United States Follicular Lymphoma Therapeutic Market Forecast
10.2.2 Canada Follicular Lymphoma Therapeutic Market Forecast
10.2.3 Mexico Follicular Lymphoma Therapeutic Market Forecast
10.2.4 Brazil Follicular Lymphoma Therapeutic Market Forecast
10.3 APAC Follicular Lymphoma Therapeutic Forecast by Region (2025-2030)
10.3.1 China Follicular Lymphoma Therapeutic Market Forecast
10.3.2 Japan Follicular Lymphoma Therapeutic Market Forecast
10.3.3 Korea Follicular Lymphoma Therapeutic Market Forecast
10.3.4 Southeast Asia Follicular Lymphoma Therapeutic Market Forecast
10.3.5 India Follicular Lymphoma Therapeutic Market Forecast
10.3.6 Australia Follicular Lymphoma Therapeutic Market Forecast
10.4 Europe Follicular Lymphoma Therapeutic Forecast by Country (2025-2030)
10.4.1 Germany Follicular Lymphoma Therapeutic Market Forecast
10.4.2 France Follicular Lymphoma Therapeutic Market Forecast
10.4.3 UK Follicular Lymphoma Therapeutic Market Forecast
10.4.4 Italy Follicular Lymphoma Therapeutic Market Forecast
10.4.5 Russia Follicular Lymphoma Therapeutic Market Forecast
10.5 Middle East & Africa Follicular Lymphoma Therapeutic Forecast by Region (2025-2030)
10.5.1 Egypt Follicular Lymphoma Therapeutic Market Forecast
10.5.2 South Africa Follicular Lymphoma Therapeutic Market Forecast
10.5.3 Israel Follicular Lymphoma Therapeutic Market Forecast
10.5.4 Turkey Follicular Lymphoma Therapeutic Market Forecast
10.5.5 GCC Countries Follicular Lymphoma Therapeutic Market Forecast
10.6 Global Follicular Lymphoma Therapeutic Forecast by Type (2025-2030)
10.7 Global Follicular Lymphoma Therapeutic Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Follicular Lymphoma Therapeutic Product Offered
11.1.3 Bayer Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Biogen
11.2.1 Biogen Company Information
11.2.2 Biogen Follicular Lymphoma Therapeutic Product Offered
11.2.3 Biogen Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Biogen Main Business Overview
11.2.5 Biogen Latest Developments
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Information
11.3.2 F. Hoffmann-La Roche Follicular Lymphoma Therapeutic Product Offered
11.3.3 F. Hoffmann-La Roche Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 F. Hoffmann-La Roche Main Business Overview
11.3.5 F. Hoffmann-La Roche Latest Developments
11.4 Gilead
11.4.1 Gilead Company Information
11.4.2 Gilead Follicular Lymphoma Therapeutic Product Offered
11.4.3 Gilead Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Gilead Main Business Overview
11.4.5 Gilead Latest Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Follicular Lymphoma Therapeutic Product Offered
11.5.3 Merck Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Merck Main Business Overview
11.5.5 Merck Latest Developments
11.6 Celldex
11.6.1 Celldex Company Information
11.6.2 Celldex Follicular Lymphoma Therapeutic Product Offered
11.6.3 Celldex Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Celldex Main Business Overview
11.6.5 Celldex Latest Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Information
11.7.2 Boehringer Ingelheim Follicular Lymphoma Therapeutic Product Offered
11.7.3 Boehringer Ingelheim Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Boehringer Ingelheim Main Business Overview
11.7.5 Boehringer Ingelheim Latest Developments
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Information
11.8.2 Bristol-Myers Squibb Follicular Lymphoma Therapeutic Product Offered
11.8.3 Bristol-Myers Squibb Follicular Lymphoma Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Bristol-Myers Squibb Main Business Overview
11.8.5 Bristol-Myers Squibb Latest Developments
12 Research Findings and Conclusion